NCT07422038 · NOT YET RECRUITING
BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention
BioMIND is testing whether a nurse-led triage tool can get people with memory concerns to Alzheimer's biomarker testing faster — things like blood tests, lumbar punctures, and amyloid PET scans. The earlier pilot cut time to diagnosis from 533 days to 195 days. This next phase measures whether streamlining access to those tests at a Canadian memory clinic can be done reliably and equitably. The phase is unspecified — this reads more as a healthcare delivery study than a drug trial.
You may qualify if
- Individual with MCI or early dementia (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA)
- MoCA score must be 10 to 28 inclusive
- Age 50 to 90 years inclusive
You're excluded if
- Participants who fulfill diagnostic criteria for MCI or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (eg, MCI/dementia due to frontotemporal lobar degeneration, diffuse Lewy body disease, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, etc).
- Presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest Huntington's disease, multiple sclerosis, Parkinson's disease, Down's syndrome, active alcohol/drug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder.
- Current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures
- Pregnant women and breastfeeding mothers.
- Individuals who are unable to complete assessments in the English language.
- Individuals who cannot provide consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-19